New pill shows promise for stubborn scalp psoriasis
NCT ID NCT05478499
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an oral medication called deucravacitinib against a placebo in 154 adults with moderate-to-severe scalp psoriasis. The main goal was to see if more people achieved clear or almost clear scalp skin after 16 weeks of treatment. This is a disease-control study, meaning the treatment aims to manage symptoms rather than cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Local Institution - 0001
Hot Springs, Arkansas, 71913, United States
-
Local Institution - 0002
New Brighton, Minnesota, 55432, United States
-
Local Institution - 0003
Portland, Oregon, 97201, United States
-
Local Institution - 0004
San Antonio, Texas, 78229, United States
-
Local Institution - 0005
Pittsburgh, Pennsylvania, 15213, United States
-
Local Institution - 0006
Norfolk, Virginia, 23502, United States
-
Local Institution - 0007
Indianapolis, Indiana, 46256, United States
-
Local Institution - 0008
Beverly, Massachusetts, 01915, United States
-
Local Institution - 0011
Mahlow, 15831, Germany
-
Local Institution - 0012
Lübeck, 23538, Germany
-
Local Institution - 0013
Frankfurt am Main, Hesse, 60590, Germany
-
Local Institution - 0014
Rzeszów, 35-055, Poland
-
Local Institution - 0015
Wroclaw, 51-685, Poland
-
Local Institution - 0017
Lodz, 90-436, Poland
-
Local Institution - 0019
Paris, 75010, France
-
Local Institution - 0022
Rockville, Maryland, 20850, United States
-
Local Institution - 0026
Krakow, 30438, Poland
-
Local Institution - 0031
London, Greater London, SE1 9RT, United Kingdom
-
Local Institution - 0033
Houston, Texas, 77004, United States
-
Local Institution - 0038
Witten, Deutschland, 58454, Germany
-
Local Institution - 0039
Southampton, HAMPSHIRE, SO16 6DU, United Kingdom
-
Local Institution - 0040
Romans-sur-Isère, 26102, France
-
Local Institution - 0041
Louisville, Kentucky, 40217, United States
-
Local Institution - 0044
Rouen, 76031, France
-
Local Institution - 0045
Salford, Greater Manchester, M6 8HD, United Kingdom
-
Local Institution - 0047
Bloomfield Hills, Michigan, 48302, United States
-
Local Institution - 0048
Hamburg, 20246, Germany
-
Local Institution - 0049
East Windsor, New Jersey, 08520, United States
-
Local Institution - 0051
Kew Gardens, New York, 11415, United States